



UNITED STATES PATENT AND TRADEMARK OFFICE



IPW
Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

COPY MAILED

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
CORPORATE INTELLECTUAL PROPERTY
P.O. BOX 8097
EMERYVILLE, CA 94662-8097

JUN 10 2009

OFFICE OF PETITIONS

In re Application of
David W. Morris, et al.
Application No. 10/539,228
Filed: October 28, 2005
Attorney Docket No. PP23370.0003/20366-036US1

ON PETITION

This is a decision in response to the petition, filed April 29, 2009, to revive the above-identified application under the provisions of 37 CFR 1.137(b).

The petition is **GRANTED**.

The application became abandoned for a failure to reply in a timely manner to a non-final Office action mailed April 9, 2008, which set a shortened statutory period for reply of three (3) months. No extension of time under the provisions of 37 CFR 1.136(a) was obtained. Accordingly, the application became abandoned on July 9, 2008. A Notice of Abandonment was mailed on October 30, 2008. In response, on April 29, 2009, the present petition was filed.

There is no indication that the person signing the instant petition was ever given a power of attorney or authorization of agent to prosecute the above-identified application. However, in accordance with 37 CFR 1.34(a), the signature of David A. Gay appearing on the petition shall constitute a representation to the United States Patent and Trademark Office that he is authorized to represent the particular party on whose behalf he acts. While a courtesy copy of this decision is being mailed Mr. Gay, all future correspondence will be directed solely to the address of record.


The petition satisfies the requirements of 37 CFR 1.137(b) in that petitioner has supplied (1) the reply in the form of amendment; (2) the petition fee of \$1,620; and (3) an adequate statement of unintentional delay¹.

¹ 37 CFR 1.137(b)(3) requires a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional. While the statement is not made by an attorney of record, such statement is being treated as having been made as the result of a reasonable inquiry into the facts and circumstances of such delay. See 37 CFR 10.18(b) and Changes to Patent Practice and Procedure; Final Rule Notice, 62 Fed. Reg. 53131, 53178 (October 10, 1997), 1203 Off. Gaz. Pat. Office 63, 103 (October 21, 1997). In the event that such an inquiry has not been made, petitioner must make such an inquiry. If such inquiry results in the discovery that it is not correct that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional, petitioner must notify the Office.

An extension of time under 37 CFR 1.136 must be filed prior to the expiration of the maximum extendable period for reply. *See In re Application of S.*, 8 USPQ2d 1630, 1631 (Comm'r Pats. 1988). Since the \$1,110 extension of time fee submitted with the petition on May 2, 2008 was subsequent to the maximum extendable period for reply, this fee is unnecessary and will be credited to petitioner's deposit account.

The application is being referred to Technology Center AU 1643 for appropriate action by the Examiner in the normal course of business on the reply received April 29, 2009.

Telephone inquiries concerning this decision should be directed to the undersigned at (571) 272-3204. Inquiries relating to further prosecution should be directed to the Technology Center.



Sherry D. Brinkley
Petitions Examiner
Office of Petitions

cc: DAVID A. GAY
4370 LA JOLLA VILLAGE DRIVE, SUITE 700
SAN DIEGO, CA 92122

Application Number Information

Application Number: **10/539228** [Order This File Assignments](#)

Filing or 371(c) Date: **10/28/2005** [eDan](#)

Effective Date: **06/17/2005**

Application Received: **06/17/2005**

Pat. Num./Pub. Num: **/20060154250**

Issue Date: **00/00/0000**

Date of Abandonment: **00/00/0000**

Attorney Docket Number:
PP23370.0003/20366-036US1

Status: **66 /WITHDRAWN ABANDONMENT, AWAITING EXAMINER ACTION**

Confirmation Number: **4557** [Oral Hearing: NO](#)

Title of Invention: **NOVEL COMPOSITIONS AND METHODS IN CANCER**

Examiner Number: **76561 / HOLLERAN, ANNE**

Group Art Unit: **1643** [IFW Madras](#)

Class/Subclass: **435/325.000**

Lost Case: **NO**

Interference Number:

Unmatched Petition: **NO**

L&R Code: Secrecy Code:**1**

Third Level Review: **NO** [Secrecy Order: NO](#)

[Status Date: 06/10/2009](#)

Bar Code	PALM Location	Location Date	Charge to Loc	Charge to Name	Employee Name	Location
10539228SA	9200	05/05/2009	No Charge to Location	No Charge to Name	CHERENFANT,JOHANNE	

Appln Info

[Contents](#)

[Petition Info](#)

[Atty/Agent Info](#)

[Continuity/Reexam](#)

[Foreign Data](#)

Search Another: Application #

[Search](#)

or Patent# [Search](#)

PCT / **/**

[Search](#)

or PG PUBS #

[Search](#)

Attorney Docket #

[Search](#)

Bar Code #

[Search](#)

To go back, right click here and select Back. To go forward, right click here and select Forward. To refresh, right click here and select Refresh.

Back to [OASIS](#) | Home page

http://EXPOWEB1:8001/cgi-bin/expo/GenInfo/snquery.pl?APPL_ID=10539228